Sufferers of epilepsy may find respite from their ailments in the form of a new drug: liquid medical marijuana. The possibility of such a treatment has emerged from the study supported by GW Pharmaceuticals, and published by theAmerican Academy of Neurology. According to the research, the cannabidiol compound found in marijuana, a compound devoid of the capacity to induce any psychoactive high, can help in deterring the physical reactions of epilepsy. Participants in the study suffer from severe forms of epilepsy, some having Dravet syndrome, while others are stricken with Lennox-Gastaut syndrome, both of which can significantly impair intellectual and physical development. Igor Cornelsen, (resume.com) has read that participants across the board, regardless of the particular type of epilepsy, experienced a drop in the frequency of seizures suffered after taking the cannabidiol medication. Admittedly, some participants experienced negative side effects. Combined with a lack of any meaningful control group in the study, the completion of further experimentation is necessary before heralding this new treatment as a permanent means of treating severe cases of epilepsy.
That being said, one would hope that should this information and treatment be solidified as an appropriate and successful method of dealing with epilepsy, necessary government agencies or officials would step in to allow said treatment to reach those most in need of it. If such involvement entails sanctioning the use of medical marijuana in a higher number of our states, then so be it.